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ABSTRACT 
Background 
Hypertensive disorders are major complications of pregnancy and are the commonest direct cause of 
maternal death in South Africa. The objective was to quantify the level of circulating cell free fetal DNA 
(cffDNA) and cell free total DNA (cftDNA) in Black South African women with gestational hypertension 
and preeclampsia. 
Methods  
This study is a prospective cross-sectional study involving 39 normotensive pregnant women (controls), 37 
women with preeclampsia (PE) and 23 with gestational hypertension (GH), all recruited during the antenatal 
period from a regional health care facility, South of Durban, KwaZulu-Natal province, South Africa. 
Preeclampsia was classified according to the guidelines of the International Society for the Study of 
Hypertension in Pregnancy (ISSHP) into severe preeclampsia (SPE), mild to moderate preeclampsia 
(MPE), early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE). Both cffDNA and cftDNA 
were quantified using real-time qPCR by exploring the difference in methylation pattern of the RASSF1A 
gene promoter in maternal plasma. 
Results  
The levels of circulating cffDNA and cftDNA were significantly higher in patients with PE compared to 
the levels in the controls and in patients with GH (p<0.001). There was no alteration in the level of cffDNA 
and cftDNA in GH compared to controls (p > 0.05). There was a significant increase in the level of cffDNA 
and cftDNA in SPE in contrast to the concentration in MPE (p<0.05). There was no difference in the level 
of cffDNA and cftDNA in EOPE compared to LOPE (p > 0.05). 
Discussion/Conclusion 
The use of RASSF1A gene as a universal fetal DNA marker has helped improve non-invasive prenatal 
diagnosis and monitoring of pregnancy complications. Our results indicate that circulating cffDNA and 
cftDNA are elevated in preeclampsia and consideration needs to be given for it to be used as a marker. The 
level of severity of PE may be a factor that influences the level of these markers in maternal plasma.
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1 CHAPTER 1: BACKGROUND AND LITERATURE REVIEW 
1.1 Background  
Pregnancy-induced hypertension (PIH) such as gestational hypertension, preeclampsia, superimposed 
preeclampsia and eclampsia is an abnormal elevation in blood pressure diagnosed after the 20th  week of 
pregnancy, with or without the presence of protein in the urine (Watanabe et al., 2013). The cause of 
hypertension in pregnancy is unknown and it’s a great health concern in both developing and advanced 
economies (Hutcheon et al., 2011).  
The magnitude of the burden caused by hypertensive disorders of pregnancy (HDP) is felt more so by 
developing economies, where it accounts for most of the maternal and fetal death recorded globally 
(Osungbade and Ige, 2011). This is because most developing countries lack basic health care facilities, 
budgetary allocation to the health sector is not adequate, and lack access to timely and efficient prenatal 
care (Ghulmiyyah and Sibai, 2012). For a long time, it has been the priority of the United Nations to reduce 
maternal death, but this goal is still far from been achieved in developing countries (Say et al., 2014).  
PIH such as gestational hypertension (GH) and preeclampsia (PE) are common obstetrical complications 
of gestation. These conditions are a leading cause of maternal morbidity and mortality (Sibai, 2011). These 
disorders are associated with preterm delivery, maternal and fetal mortality (Barra et al., 2012).  
The development of the placenta in humans is a complex and highly regulated process involving the 
invasion of the uterus by cells of the cytotrophoblast, remodelling the placental vasculature and converting 
them into large conduits (Eastabrook et al., 2011). Spiral artery remodelling is defective in PE. It is believed 
that this aberration in placentation occurs in early stages of pregnancy leading to diminished blood flow to 
the placenta, followed by ischaemia of the placenta (Naljayan and Karumanchi, 2013); releasing placental 
derived particles/factors. These placenta-derived microparticles, factors and or debris are able to trigger an 
exaggerated inflammatory response as seen in obstetric complications like preeclampsia (Redman and 
Sargent, 2001).  In particular, endothelial dysfunction is seen as a hallmark of PE, triggered by this 
inflammatory response (Tannetta and Sargent, 2013). 
Other factors implicated in the development of preeclampsia include alterations in the circulating level of 
pro-inflammatory substances, damage to vascular endothelium and placental hypoxia. Delivery is 
considered a remedy as these conditions resolve with delivery of the placenta (Magee et al., 2014, Mol et 
al., 2016). 
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1.1.1 Prevalence  
Globally HDP is responsible for about 62,000 to 77,000 maternal deaths yearly, which  is about 18% of all 
maternal deaths (Abalos et al., 2013). Most of the cases of HDP are seen in low-income countries (Abalos 
et al., 2013). The risk of a woman dying from hypertensive complications during pregnancy is about 1 in 
3800 women in the developed countries compared to the figure in Sub-Saharan Africa which is very high, 
viz. 1 in 39 (Abalos et al., 2013). 
In South Africa, HDP continues to be the most dominant cause of maternal death (Saving Mothers Report, 
2015). There was a total of 4452 maternal deaths recorded in South Africa from 2011 – 2013, and maternal 
deaths due to hypertensive disorders of pregnancy was 14.8 percent of this total figure at a national level. 
In the KwaZulu-Natal Province, hypertensive disorders of pregnancy accounted for about 8.3 percent of 
maternal deaths (Saving Mothers Report, 2015). 
1.1.2 Risk factors of hypertension in pregnancy 
Certain risk factors are known to predispose women to develop hypertension in pregnancy. These factors 
include previous history of hypertension, vascular disease, and renal complications, obesity, and the  
presence of medical conditions such as diabetes (Villar et al., 2006). Also, other known risk factors of 
hypertension in pregnancy include; nulliparity, an age of ≥ 40 years, a long interval between pregnancies, 
and multiple gestations (Lin et al., 2015, Villar et al., 2006).     
Factors that predispose women to develop preeclampsia include genetic factors such as family history of 
the disease (Lin et al., 2015, Powe et al., 2011). The change in paternity from a previous pregnancy and the 
use of barrier contraception resulting in limited exposure to paternal antigens, predisposes  women to 
preeclampsia (Powe et al., 2011).  
1.1.3 Pathogenesis of hypertension in pregnancy 
The mechanism of development of PIH remains elusive despite the large amount of resources dedicated to 
the study of these conditions. Research has shown that the underlying etiological factor responsible for the 
development of PIH is diminished uteroplacental blood flow resulting from impaired trophoblast invasion 
of the placental spiral arteries (Barra et al., 2012).  
The diminished placental blood flow results in ischaemia of placenta cells followed by the destruction of 
these cells. The contents of these necrotic cells are released into the circulation leading to stimulation of the 
maternal vascular endothelium and its subsequent dysfunction. (Barra et al., 2012, Shah, 2007). Oxidative 
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stress resulting from dysfunction of the maternal vascular endothelium also contributes to the model of 
target organ injury seen in conditions like preeclampsia (Shah, 2007). More recently more defined particles 
have been identified such a microvescicles (Tannneta and Sergent, 2013) impacting on the endothelium. 
The development of preeclampsia occurs in stages (Figure 1); viz. the pre-clinical stage and the clinical 
stage (Tannetta and Sargent, 2013). The first stage (the preclinical stage) of the disease, which is 
characterised by poor placentation, shallow invasion of cytotrophoblast cells, abnormal remodelling of the 
placenta spiral artery and reduced placental perfusion (Tannetta and Sargent, 2013). As a result of the 
abnormally remodelled spiral arteries, the placenta becomes exposed to oxidative stress, (Redman, 2011), 
and destruction of the syncytial architecture occurs. 
 
Figure 1. Diagrammatic representation of the stages of pre-eclampsia. Abnormal remodelling of spiral 
artery which results from poor placentation causes release of placental particles or factors responsible for 
initiation of a systemic inflammatory response and dysfunction of the maternal vascular endothelium which 
manifests as the clinical signs seen in PE (Borzychowski et al., 2006).  
 
The second stage of preeclampsia (clinical stage) develops from the destruction of the syncytial 
architecture, which causes the release of cellular content into maternal circulation (Granger et al., 2001, 
Steegers et al., 2010); a concept which has been promulgated over the years.  Features of the clinical stage 
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of preeclampsia include increased peripheral vasoconstriction while arterial compliance is diminished 
(Tannetta and Sargent, 2013). Molecules released by the stressed placenta include ‟soluble vascular 
endothelial growth factor receptor-1 (VEGFR1 or the sFlt-1) and soluble endoglin (sENG)” (Redman, 
2011). These molecules are known to affect the orientation of the fenestrated endothelium for which 
vascular endothelial growth factor (VEGF) is  important for its integrity (Redman, 2011). The end result is 
the disorientation of the fenestrated endothelium resulting in protein leakage into the urine (Craici et al., 
2013). Podocytes are pathologically affected and released into the urine of preeclamptic patients (Craici et 
al., 2013).  
This concept of an ischemic placenta, resulting in the release of cellular debris, is currently evolving to 
include particles such as microvesicles, fetal DNA and exosomes. They play a significant role in initiating 
systemic inflammatory response and endothelial dysfunction (Tannetta and Sargent, 2013). 
1.1.3.1 The role of angiogenic and antiangiogenic molecules in preeclampsia 
Ischemia of the placental cells results in them secreting soluble factors in to circulation, these 
factors which are anti-angiogenic may cause maternal endothelial dysfunction (Tanneta and 
Sargent, 2013). Disruption in the balances between angiogenic and antiangiogenic factors is 
critical to the pathogenesis of PE. Two antiangiogenic factors, soluble fms-like tyrosine kinase 1 
(sFlt-1) and soluble endoglin (sEng) have been shown to play a great role in the pathogenesis of 
PE (Redman, 2011). 
The anti-angiogenic molecule sFlt-1 is a splice variant of the membrane bound VEGF receptor 
Flt1, it is mainly secreted and released into the circulation by syncytiotrophoblast cells (Redman 
and Sargent 2001). Elevated levels of sFlt-1 is associated with diminished placental growth factor 
(PLGF) and vascular endothelial growth factor (VEGF) signalling.  Soluble fms-like tyrosine 
kinase-1 prevents VEGF and PLGF from carrying out their normal function by binding to them in 
circulation and inhibiting their interaction with receptors meant for their function (Goulopoulou 
and Davidge, 2015).    
Another peptide molecule indicted in the pathogenesis of PE is soluble endoglin (sEng), it is an 
antiangiogenic protein. This molecule is highly expressed on endothelial cell membranes, 
syncytiotrophoblast cells and invading cytotrophoblast cells (Powe et al., 2011). Soluble 
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endoglinng may combine with sFlt-1 and cause amplification of vascular injury (Powe et al., 
2011).  
1.1.4 Classification of pregnancy induced hypertension  
PIH is classified into the following categories; preeclampsia, gestational hypertension, superimposed 
preeclampsia and eclampsia (Watanabe et al., 2013). 
1.1.4.1 Preeclampsia 
Preeclampsia is a HDP that occurs after the 20th week of gestation. It is characterised by a systolic blood 
pressure ≥ 140mmHg and or a diastolic blood pressure ≥ 90mmHg along with proteinuria (≥ 0.3g in a 24-
hour urine sample) (Magee et al., 2014).  It is accountable for most of the maternal and fetal deaths caused 
by hypertensive disorders of pregnancy in developing countries (Mol et al., 2016). 
Women with preeclampsia if not given adequate medical attention will develop severe conditions such as 
seizures which lead to coma (Souza et al., 2013). Preeclampsia is also associated with conditions like 
spontaneous abortion, fetal growth restriction, and preterm delivery (see review by (Mol et al., 2016).  
Preeclampsia impacts on almost all organ systems and causes devastating changes in the intrauterine milieu 
by modifying hormonal signalling patterns, and causes activation of unfavourable cellular signalling 
detrimental to the development of the fetus (Goulopoulou and Davidge, 2015).  
1.1.4.2 Gestational hypertension 
GH is new onset hypertension in pregnant women who were previously normotensive prior to becoming 
pregnant, after the 20th week of gestation (Cruz et al., 2012).  This HDP is characterised by a blood pressure 
of ≥ 140/90 mmHg, presenting without proteinuria (Tranquilli et al., 2014).  
Some authors have stated that GH, may share similar risk factors and pathologic features with PE, but is 
still a separate condition (Li et al., 2016, Villar et al., 2006).  Others have pointed out that GH is likely to 
progress to PE (Romero-Arauz et al., 2014, Saudan et al., 1998, Sibai, 2003). 
The dangers of the complications associated with this disorder are dependent on the maternal age of 
gestation at onset, as well as the maternal and fetal health at the point when the diagnosis is made (Sibai, 
2011). Development of GH during pregnancy is a warning that a woman may develop essential 
hypertension in the future (Cruz et al., 2012). 
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1.1.4.3 Superimposed preeclampsia 
This is new onset proteinuria in women with hypertension which predates pregnancy but no proteinuria 
preceding the 20th week of pregnancy (Watanabe et al., 2013). Superimposed preeclampsia may develop 
from already existing chronic hypertension, and this condition is connected with grave maternal and fetal 
complications in pregnancy. Most cases of superimposed preeclampsia occur at term (Magee et al., 2014). 
Superimposed preeclampsia may also be triggered by renal complications before the 20th week of 
pregnancy, which is complemented by the development of new onset proteinuria and elevation of blood 
pressure above normal after the 20th week of pregnancy (Watanabe et al., 2013).  
1.1.4.4 Eclampsia  
Severe forms of PE may result in eclampsia, this is the onset of convulsive seizures in a pregnant woman 
with hypertension induced by pregnancy. The Manifestation of these seizures may occur before labour, 
during labour or after labour (Watanabe et al., 2013). The mechanism of development of eclamptic seizures 
still remains to be proven. However factors thought to be responsible for eclamptic seizures include cerebral 
vasospasm and cerebral oedema amongst other factors (Sibai, 2003).   
Eclampsia accounts for the high incidence of maternal mortality in low-resource countries. Complications 
arising as a result of eclampsia are more severe in women who develop this disorder during the antepartum 
period, especially where it occurs distant to term (Ghulmiyyah and Sibai, 2012).     
1.1.5 Sub classification of Preeclampsia 
Preeclampsia (PE) can be sub classified based on severity and onset (Watanabe et al., 2013). Based on 
severity, it is classified as follows; 
I. Mild PE which is characterised by a blood pressure of ≥ 140/90 mmHg but less than 160/110 
mmHg, and proteinuria of  ≥ 300mg but not more than 2.0g in a 24-hour urine sample (or  2 pluses 
(+) on a dipstick) (Watanabe et al., 2013).   
II. Severe PE is characterised by a blood pressure ≥ 160/110 mmHg and urinary protein concentration 
> 2.0g in a 24-hour urine sample (or  3 pluses (+) on a dipstick) (Watanabe et al., 2013).  
Based on onset, early onset PE occurs before 34 weeks (≤ 33 weeks 6 days) of pregnancy. Late onset PE is  
PE at 34 or after 34 weeks post conception (Lisonkova and Joseph, 2013). 
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1.2 Cell free DNA and Cell free fetal DNA  
Circulating cell free DNA (cfDNA) is extracellular DNA found circulating freely in plasma (Barra et al., 
2015). Circulating cfDNA in human plasma was first detected by Mandel and Metais (Mandel, 1948), 
which was even before DNA was described as a double helix by Watson and Crick (Watson and Crick, 
1953). In 1997, Lo et al discovered circulating cell free fetal DNA in maternal blood (Lo et al., 1997).  
The use of cell free total DNA (cftDNA) and cell free fetal DNA (cffDNA) in molecular diagnostics has 
aided laboratory investigations relating to the physiologic and pathologic state during the course of 
pregnancy (Alberry et al., 2009). This discovery made by Lo et al., has paved a way for non-invasive 
prenatal diagnosis (NIPD), this fit was possible by detecting the presence of  fetal Y-chromosomal segments 
in plasma of pregnant women (Lo et al., 1997).   
The use of Cell free DNA testing, independently or in conjunction with other screening test procedures, is 
beginning to replace older testing methods, thus revolutionizing diagnosis for fetal abnormalities and also 
helping to diagnose pathological conditions in pregnant women (Cuckle et al., 2015).  
1.2.1 Origin of cell free DNA and Cell free fetal DNA in maternal circulation 
A greater portion of circulating DNA in maternal circulation during the course of pregnancy is of maternal 
origin; with the fetal fraction comprising just about 9 % in the early part of pregnancy and later increases 
to about 20% as pregnancy progresses (Hill et al., 2012). The source of circulating cfDNA in normal 
individuals and also in pregnant women is not clear. However, it is known that the pool of cfDNA in 
circulation is from solid organs, and also from haematopoietic cells (Lui et al., 2002). In the case of the 
latter, this  molecule is derived from the turn-over of short-lived hematopoietic cells (Hahn et al., 2014). 
Postulations about the placenta being the originating source of circulating cffDNA are supported by 
detection of circulating cffDNA in anembryonic pregnancies, as well as the homogeneity of epigenetic 
markers of circulating cffDNA and the placenta tissues (Alberry et al., 2007, Chim et al., 2005). The human 
placenta is dynamic and constantly undergoing villous trophoblast turnover. This releases apoptotic 
placental material into the circulation. This physiological process is responsible for the release of cell free 
nucleic acids into the plasma. In pathological conditions such as preeclampsia the level is altered (Huppertz, 
2004, Taglauer et al., 2014). 
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1.2.2 Circulating Cell free fetal DNA and Cell free total DNA (cffDNA) as indicators of placental 
condition 
Circulating cffDNA and cftDNA are markers that can be used to establish the physiologic and pathologic 
states during the course of pregnancy. Previous studies have shown an increase in circulating cftDNA and 
cffDNA in PE and in pregnancies that experience fetal growth restriction (Alberry et al., 2009, Sekizawa 
et al., 2003, Sifakis et al., 2009).  
Due to the continuous villous trophoblast change as pregnancy progresses, apoptotic materials including 
cftDNA are released into the circulation (Taglauer et al., 2014). The release of cffDNA and cftDNA is 
linked to the stages of placental development (Taglauer et al., 2014). Since the concentration of circulating 
cffDNA and cftDNA are linked to placental morphogenesis, physiological or pathological conditions that 
affects the placenta will also directly impact the circulating levels of cfDNA and cffDNA (Taglauer et al., 
2014). 
1.2.3 Quantification of circulating Cell free fetal using the Ras Association Domain Family - 1 
isoform A (RASSF1A) gene. 
The measurement of cffDNA routinely for NIPD in complications of pregnancy, such as preeclampsia, 
depends on the presence of a paternally inherited gene sequence (relating to the Y chromosome) (Alberry 
et al., 2009, Lazar et al., 2009, Lo et al., 1997, Sekizawa et al., 2001). Availability of a universal marker 
for the detection of cffDNA in the diagnosis of complications of pregnancy is of great importance (Chan et 
al., 2006, Salvianti et al., 2015). Fetal DNA markers of NIPD frequently used such as the Y-chromosomal 
sequences are not able to serve as positive controls in cases where the fetus the mother is carrying is a 
female, as the Y-chromosomal sequence is seen only in pregnancies with a male fetus (Chan et al., 2006).  
The development of a universal marker for fetal DNA detection irrespective the sex of the fetus can be 
explored by the use of an epigenetic approach to distinguish circulating cfDNA of maternal origin from that 
of fetal origin (Chim et al., 2005). In the quest to develop a universal marker for the detection of cffDNA 
in circulation, Chan et al., (2006) have shown that the promoter of the RASSF1A tumor suppressor gene 
can be employed as a universal marker for circulating cffDNA in maternal plasma. This is due to the fact 
that the promoter of the RASSF1A gene of placenta origin is hypermethylated (figure 2), while that in the 
maternal blood is hypomethylated (Zejskova et al., 2010).  
By the use of restriction enzymes such as the BstUI (figure 2) on circulating DNA extracted from the 
maternal plasma, the RASSF1A sequence of maternal origin is digested because it is hypomethylated, 
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leaving behind the hypermethylated RASSF1A sequence of fetal origin (Chan et al., 2006, White et al., 
2012).  The hypermethylated RASSF1A sequence of fetal origin can then be quantified using real time 
quantitative polymerase chain reaction (RT-qPCR) to determine the circulating level of cffDNA. 
Hypermethylated DNA of fetal origin is not digested because it is resistant to methylation restriction 
enzymes, unlike the hypomethylated DNA (White et al., 2012).    
 
Figure 2. Diagrammatic representation of hypermethylated and hypomethylated RASSF1A gene. When 
RASSF1A in maternal plasma is subjected to methylation sensitive restriction enzyme such as the BstUI, 
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only the RASSF1A of fetal origin will remain in the sample as the RASSF1A of maternal origin will be 
digested owing to the fact that it is hypomethylated (Zejskova et al., 2010). 
 
 
 
1.2.4 Applications of circulating cell free DNA 
Before the development of NIPD, conventional methods of prenatal diagnosis were based on the use of 
invasive procedures (Hill et al., 2012). Clinical applications of cffDNA and cftDNA in pregnancy are based 
on the fact that there is an increase in the circulating concentration in pregnancy complications (Alberry et 
al., 2009). Several studies have reported increase in the circulating levels of cffDNA in complications of 
pregnancy (AbdelHalim et al., 2016, Kim et al., 2015, Salvianti et al., 2015).  
Asides its application in the diagnosis of pregnancy complications, it has also been of good use in the 
detection of fetal gender and the diagnosis of fetal aneuploidy (Bianchi, 2004). Determination of fetal sex 
can be performed using RT-qPCR to detect the sequences of inherited paternal Y chromosome in 
circulation. Determination of fetal sex is critical in carriers X-linked disorders (Devaney et al., 2011). With 
advances in technology and the knowledge of genetics, circulating cfDNA guarantees the use of NIPD for 
detection of autosomal dominant and recessive disorders (Hill et al., 2012).  
Conventionally, the detection of aneuploidy is done using circulating fetal cells from the amniotic fluid, but 
with the development of NIPD using circulating cfDNA, prenatal diagnosis of aneuploidy is made easier 
(Hill et al., 2012).  Fetal RhD status can be confirmed using circulating cffDNA. This is of importance in 
RhD-negative women with previous history of haemolytic disease of the new-born and with high anti-D 
antibodies (Daniels et al., 2009)  
1.3 Problem statement 
The incidence of hypertensive disorders of pregnancy in South Africa is high and remains the commonest 
direct cause of maternal mortality. No study has quantified the circulating levels of cell free fetal DNA 
(cffDNA) and cell free total DNA (cftDNA) in Black African population, hence the need for this study 
since it has been shown by previous studies that the aggressiveness of PIH differs with geographical location 
and in women of African ancestry  
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1.4 Hypothesis  
Circulating cell free fetal DNA and cell free total DNA are elevated in pregnancy induced hypertension.  
1.5 Aim  
To quantify cell free fetal DNA in normal pregnancy and in pregnancy induced hypertension. 
1.6 Objectives 
I. To quantify the circulating level of cell free fetal DNA in normal pregnancy, preeclampsia, and 
gestational hypertension.  
II. To quantify the circulating level of cell free total DNA in normal pregnancy, preeclampsia, and 
gestational hypertension.  
 
2 CHAPTER 2: MANUSCRIPT SUBMITTED TO THE INTERNATIONAL JOURNAL 
OF MOLECULAR SCIENCE (IJMS) 
2.1 Circulating Cell Free Fetal DNA and Cell Free total DNA in Black South African Women with 
Gestational Hypertension and Preeclampsia. 
Simeon Eche1, Irene Mackraj2*, Jagidesa Moodley 3 
1Department of Medical Biochemistry, University of KwaZulu-Natal, Durban, South Africa; 
echesimeon@gmail.com 
2Department of Human Physiology, University of KwaZulu-Natal, Durban, South Africa; 
mackraji@ukzn.ac.za. 
3Department of Obstetrics and Gynecology and Women’s Health and HIV Research Group, Nelson R 
Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; jmog@ukzn.c.za 
*Correspondence: Tel; 031-260 7770; mackraji@ukzn.ac.za 
Abstract: The objective was to quantify the level of circulating cell free fetal DNA (cffDNA) and cell free 
total DNA (cftDNA) in Black South African women with gestational hypertension and preeclampsia. This 
was a prospective cross sectional study involving 39 controls, 37 women with preeclampsia (PE) and 23 
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with gestational hypertension (GH). Preeclampsia was subdivided into severe preeclampsia (SPE), mild to 
moderate preeclampsia (MPE), early onset preeclampsia (EOPE) and late onset preeclampsia (LOPE). Both 
cffDNA and cftDNA were quantified using real time qPCR by exploring the difference in methylation 
pattern of the RASSF1A gene promoter in maternal plasma. The levels of circulating cffDNA and cftDNA 
were significantly higher in patients with PE compared to the levels in the controls and in patients with GH 
(p<0.001). There was no alteration in the level of cffDNA and cftDNA in GH compared to controls (p > 
0.05). There was a significant increase in the level of cffDNA and cftDNA in SPE in contrast to that in 
MPE (p<0.05). There was no difference in the level of cffDNA and cftDNA in EOPE compared to LOPE 
(p > 0.05).   
 
Keywords: cell free fetal DNA; cell free total DNA; preeclampsia; gestational hypertension 
 
1. Introduction 
The hypertensive disorders of pregnancy (chronic hypertension, gestational hypertension, 
preeclampsia, eclampsia and the HELLP syndrome) are associated with significant perinatal and maternal 
morbidity and mortality [1]. Despite the large amount of resources dedicated over the years to the study of 
these complications of pregnancy, the exact cause still remains elusive [2]. 
Globally, up to 10% of pregnancies are affected by hypertensive disorders of gestation [3]. 
Evidence points to diminished utero-placental perfusion, leading to a hypoxic placenta, as the initiating 
event in preeclampsia; which leads to the secretion of factors/debris in the circulation [4]. Factors 
implicated in the development of preeclampsia, per se, include; alterations in the circulating level of pro-
inflammatory substances, damage to vascular endothelium caused by shear stress of utero-placental blood 
flow and also by placental hypoxia; and systemic endothelial dysfunction. Because the exact cause or 
etiology of preeclampsia is not known, delivery of the baby and placenta is considered as curative [5, 6].  
During pregnancy, the placenta is constantly undergoing the process of villous trophoblast turnover 
and morphogenesis, which leads to the release of apoptotic materials and cell free nucleic acids into 
maternal circulation [7]. Since the release of circulating nucleic acids is linked to placental morphogenesis, 
pathological conditions affecting the placenta will directly impact upon the circulating levels of cell free 
DNA (cfDNA) [7]. 
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A greater percentage of cfDNA in circulation during the course of pregnancy is of maternal origin, 
the fetal fraction constitutes just 9% of the total circulating cfDNA in early pregnancy and about 20% as 
pregnancy progresses [8].The assertion that the placenta is the source of circulating fetal DNA is supported 
by the presence of fetal DNA in anembryonic pregnancies, as well as the uniformity between epigenetic 
markers of circulating  fetal DNA and the placental tissue [9, 10].   
Plasma circulating placenta-derived cfDNA can be considered as a reliable marker with potential 
uses in the diagnosis and monitoring of the development of complications during the course of pregnancy, 
especially since it is released into the maternal circulation  in the early stages of pregnancy [11].  
To the best of our knowledge there has been no study that has quantified the circulating levels of 
cfDNA in a homogenous Black African population.  The objective of our study therefore was to quantify 
circulating cell free fetal DNA (cffDNA) and cell free total DNA (cftDNA) in Black South African women 
with gestational hypertension and preeclampsia as the incidence of hypertensive disorders of pregnancy in 
South Africa is high and remains the commonest direct cause of maternal mortality [12]. 
2. Results 
2.1 Patient demographics and their clinical characteristics 
Patient demographics and their clinical characteristics are shown in table 1. There was no difference 
in maternal age and gestational age among the different groups of patients. There was a significant 
difference in the BMI of the controls compared to patients with GH (p<0.001). Also there was significant 
difference in BMI of patients with GH compared to patients with PE (p<0.001).  
Table 1. Patient demographics and clinical characteristics.  
 Control  
(n=39) 
Gestational hypertension 
 (GH) (n=23) 
Preeclampsia (PE) 
(n=37) 
Age (years) 27.7 ± 5.9 30.3 ± 4.5 27.1 ± 6.9 
BMI (kg/m2) 32.6 ± 7.1 39.8 ±6.7*µ 32.8 ± 6.8 
Primigravidae (number) 12  4  14 
Multigravidae (number) 27  19  23 
Gestational age at sampling (weeks) 35.5 ± 4.2 35.3 ± 5.6 33.6 ± 4.4 
Systolic blood pressure (mmHg) 114.7 ± 9.7 151.3 ± 8.3* 154.8 ± 14.5# 
Diastolic blood pressure (mmHg) 79.8 ± 7.8 97.8 ± 6.9 * 99.7 ± 11.0 #  
*control vs GH (p<0.05); # control vs PE (p <0.05); µ GH vs PE (p <0.05) 
BMI; body mass index 
Values are expressed as mean ± standard deviation, and number of occurrence. 
 
14 
 
2.2 cffDNA and cftDNA quantification 
Figure 1(a) shows circulating cftDNA was significantly higher in patients with PE (p < 0.001) (median 
2174.0, range 904.5 – 6871.0 genomic equivalence/ml) compared to the controls (median 673.5, range 
117.0 – 1754.0 genomic equivalence/ml) and patients with GH (median 682.0, range 226.5 – 1829.0 
genomic equivalence/ml).  There was no difference in the level of cftDNA between the controls and patients 
with GH (p>0.05). 
Figure 1(b) shows the level of circulating cftDNA in the various sub-divisions of PE. There was a 
significant difference (p<0.05) in the level of circulating total cfDNA in SPE (median 3053, range 1129 - 
6871 genomic equivalence/ml) compared to MPE (median 1878, range 904.5 - 5480 genomic 
equivalence/ml). There was no difference between EOPE (median 2518, range 1351 – 6871) and LOPE 
(median 1694, range 904.5 – 4751) (p>0.05). 
15 
 
  
                   
                                            (C)                                                                                                            (d)  
Figure 1. Box plot of cell free total DNA (cftDNA) and cell free fetal DNA (cffDNA) in controls, GH and 
PE. (a) cell free total DNA in controls, GH and PE. (b) cell free total DNA in controls and the various sub-
divisions of PE. (c) cell free fetal DNA in controls, GH and PE. (d) cell free fetal DNA in controls and the 
various sub-divisions of PE. Horizontal lines the inside box represents the median, while the whiskers 
represent the minimum and maximum values. GE (Genomic equivalent). 
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The levels of cffDNA in the various study groups are shown in figure 1(c). The level of cffDNA 
was significantly higher in PE (p < 0.001) (median 128.1, range 26.1 - 398.8 genomic equivalence/ml) 
compared to the controls (median 46.2, range 4.0 – 125.4 genomic equivalence/ml) and patients with GH 
(median 65.0, range 5.9 – 151.8 genomic equivalence/ml). No difference was seen in the levels cffDNA 
in controls compared to patients with GH (p>0.05). 
Figure 1(d) shows comparison of cffDNA between the sub-divisions of PE. There was an increase 
in the level of cffDNA in patients with SPE (median 212.6, range 26.1 – 398.3 genomic equivalence/ml) 
compared to patients with MPE (median 148.9, range 52.8 – 336.0 genomic equivalence/ml) (p < 0.05). 
There was no difference in cffDNA between EOPE (median 148.9, range 52.8 – 336.0) and LOPE (median 
125.6, range 26.1 – 398.8) (p>0.05). 
3. Discussion 
The development of a universal fetal DNA marker, such as the RASSF1A, which can be quantified 
irrespective of the sex of the fetus, has helped change the face of non-invasive prenatal diagnosis and 
improves the monitoring of pregnancy complications during the course of gestation [13]. Different studies 
have shown that circulating cffDNA regardless of the marker studied (SRY gene, DSY gene; TSPY 1 gene, 
RASSF1A gene and DSCR3 gene) [11, 14-18] is increased in preeclampsia and other complications of 
pregnancy. Though the SRY gene and the DSY gene can only be quantified in pregnancies with male fetus, 
studies have also shown that there exists strong correlation between the level of the SRY gene and 
RASSF1A [19], as well as the DSY gene and RASSF1A gene in the maternal circulation [20]. 
Several studies have used different techniques, some have used fluorescent labelled probes for the 
detection of the RASSF1A gene [13, 16], while others have used SYBR green for the detection of 
fluorescence [20, 21]. In this study we used a modified SYBR green real time PCR protocol published by 
White et al., (2012) for the detection of hypermethylated RASSF1A in maternal plasma [20]. White et al., 
(2012) found that interpretation of result was easier using SYBR green real time PCR compared to methods 
using the hydrolysis probes, and this method is easily reproducible in low resource settings [20].   
From our results, we observed that the levels of circulating cffDNA and ctfDNA were significantly 
higher in patients with PE compared to the levels in the controls and in patients with GH. There was a 3.2-
fold increase in the median level of cffDNA and cftDNA in the patients with PE compared to the levels in 
the controls and GH. Our findings are in keeping with previous studies which have also reported increases 
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in circulating cffDNA and cftDNA in the plasma of women with preeclampsia compared to controls [11, 
16]. Elevation in the level of cfDNA in PE is connected to the degree of perfusion and extent of injury to 
the placenta, which impacts upon the circulating levels of cffDNA and cftDNA [22-24]. 
There was no alteration in the level of cffDNA and cftDNA in GH compared to controls. The plasma 
concentration of cffDNA and cftDNA in PE was higher than that in patients with GH. Kim et al., (2015) 
have also reported a similar findings [16]. Some authors have stated that GH, though a hypertensive disorder 
of pregnancy, and shares similar risk factors and pathologic features with PE, is a separate condition [25, 
26].  Noori et al., (2010) have stated that the disequilibrium in the concentration of pro and anti-angiogenic 
molecules and endothelial dysfunction are unique and peculiar features of PE [27], but others point out that 
GH is likely to progress to PE and the rate of progress is dependent on the gestational age at the time of 
diagnosis of GH [28-30]. 
In our study there was 4.5 and 2.8-fold increase in the level cftDNA in SPE and MPE when 
compared to the controls, and a 5 and 3.6-fold increase in the concentration of cffDNA in SPE and MPE 
respectively. Fetal and total cfDNA were significantly elevated in patients with SPE compared to the level 
in patients with MPE. It has been reported that the circulating levels of these markers are affected by the 
severity of the disease [14, 16]. Abdelhalim et al., (2016)has reported an increase in the level of cffDNA 
and  cftDNA in patients with SPE compared to that in MPE, though these authors used different markers 
[HBB gene for estimation of cftDNA and the TSPY1 gene for quantification of cffDNA] for the 
quantification of cffDNA and cftDNA [14]. Kim et al., (2015) have also reported similar findings of an 
increase in the level of cfDNA with severity of the preeclampsia [16]. It is plausible that the finding of 
increased cfDNA in severe preeclampsia might help clinicians not only to differentiate between mild and 
severe preeclampsia but also assist in the timing of delivery. This needs further investigation.  
In the EOPE and LOPE group, there was significant increase in the level of circulating cffDNA 
and cftDNA compared to the level in the control group, but the level did not vary between EOPE and LOPE.  
This finding is in keeping with the study carried out by Papantoniou et al., (2013) who noted the level of 
cffDNA in EOPE was not different from the level in LOPE, though the number EOPE to LOPE in their 
study was 2 out of 24 preeclamptic women [31].  
4. Materials and Methods  
4.1 Study design, setting and Patient population  
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Ethical approval for this study was obtained from the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BREC- No. 379/15). This study was done prospectively on samples obtained 
from patients in the antenatal ward of a regional hospital in the south of Durban, South Africa.  
Pregnant women in the antenatal period without any history of obstetric complications served as 
controls. Gestational hypertension was defined as new onset hypertension (a blood pressure of ≥ 
140/90mmHg) without the presence of protein in the urine after the 20th week of gestation [5, 32]. 
Preeclampsia was defined as new onset hypertension, characterized by a blood pressure of ≥ 140/90mmHg 
with the presence of protein in the urine ≥ 300mg in a 24 hour urine sample (or a value of ≥ 1+ on dipstick) 
after the 20th week of gestation [5, 32]. Blood pressure measurement as well as dipstick proteinuria values 
were repeated after about 4 to 6 hours later to confirm the earlier diagnosis [32].  
Preeclampsia was subdivided into mild to moderate preeclampsia (MPE) defined by a blood 
pressure of ≥ 140/90mmHg and ≤ 159/109 mmHg and proteinuria ≥ 300mg in a 24-hour urine sample but 
not exceeding 2.0 g or a concentration of 1+ to 2+ on dipstick [5]. Severe preeclampsia (SPE) was defined 
by a blood pressure of ≥160/110 mmHg and proteinuria greater than 2.0 g in a 24 hour urine sample or > 
+++ on a dipstick [5]. Based on onset of preeclampsia, early onset preeclampsia (EOPE) was defined as PE 
before 34 weeks (≤ 33 weeks 6 days) of pregnancy. Late onset preeclampsia (LOPE) was defined as PE at 
34 or after 34 weeks of gestation [33]. 
Women having the following medical conditions were excluded from the study; chronic 
hypertension, cardiovascular or renal disease, diabetes mellitus, bleeding disorders and previous history of 
any medical conditions.  
4.2 Blood collection 
5 ml of blood was obtained from the patients into a sterile EDTA tube and processed within one 
hour of collection. Blood samples were spun at 1600g for 10 minutes. The supernatant plasma was 
transferred into another tube and spun for the second time at 14000g for 10 minutes. The supernatant was 
stored at minus (-) 80o C pending DNA extraction.  
4.3 DNA extraction  
Plasma cfDNA was extracted using the Roche high pure PCR template preparation kit (Roche 
Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. 200 microliter of plasma 
was used and the DNA was eluted in a final volume of 200 microliters.  
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4.4 Quantitative Real time polymerase chain reaction for quantification of cffDNA and cftDNA using the 
Ras association domain family 1 isoform A (RASSF1A) gene. 
We used a modified Real time PCR protocol published by White et al., for the detection of 
hypermethylated RASSF1A in maternal plasma [20]. We used the 2X light cycler 480 SYBR green 1 master 
mix on the Roche light cycler 96. A concentration of 1.0µM/L of both forward and reverse primers was 
used. The primer sequences used were; RSF-b151F 5’-AGC CTG AGC TCA TTG AGC TG-3’, RSF-
dsgnR 5’-ACC AGC TGC CGT GTG G-3’ [13].  
Fetal cfDNA was quantified using the methylated form of RASSF1A promoter after the 
unmethylated cfDNA was digested using methylation sensitive enzyme.  5 µl of the extracted cfDNA was 
digested using 10 units of Bsh1236I (Thermo Fisher scientific Inc, USA), total reaction volume was 20µl 
at a temperature of 370C for 16 hours. After enzyme treatment, 5µl of the enzyme treated cfDNA underwent 
a qPCR reaction for the RASSF1A promoter, with a final reaction volume of 20µl. The control for the 
enzymatic reaction was the β-actin gene which targets the unmethylated sequence of the β-actin promoter.  
A fully complete enzyme digestion of the hypomethylated cffDNA was confirmed by the absence of the β-
actin gene amplification signals. The primer sequence used for the β-actin gene are as follows; Actin-163F 
5’-GCG CCG TTC CGA AAG TT-3’, Actin-298R 5’-CGG CGG ATC GGC AAA-3’ [13]. Total cfDNA 
was quantified using the undigested extracted cell free DNA. A series of different concentrations of 
standards was made using genomic DNA (10ng/µL) to construct the standard curve. Standards were 
included in all qPCR runs. Both standard standards and test samples analyzed in duplicate. Results obtained 
at the end of qPCR were expressed as genomic equivalence per ml, using a conversion factor of 6.6pg 
DNA/ml of plasma [13]. 
4.5 Statistical Analysis 
Data analysis of the results was done using the GraphPad Prism 5.03 (Graph Pad software Inc., 
California). The Mann-Whitney U-test was used to compare experimental results between two groups. 
Quantitative variables across several groups was compared using the Kruskal–Wallis test. Categorical 
variables were compared using the Fisher Exact test. A p-value less than 0.05 was considered significant.  
5. Conclusions  
Our results indicate that circulating cffDNA and cftDNA is elevated in preeclampsia supporting its 
use as a potential marker in pregnancy related hypertention. Our results also indicate that that the level of 
severity of PE may be a factor that influences the level of these markers in maternal plasma in PE. We 
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propose that the use of cfDNA alone or in combination with other tests be fully standardized for the 
diagnosis and monitoring of preeclampsia.  
6. Strength and Limitation of the study 
This is the first study to quantify circulating cffDNA and cftDNA in a homogenous Black African 
population in which hypertensive disorders of pregnancy may be more prevalent than in Caucasian 
population. The limitations of this study is that we did not factor in the gender of the fetus. 
Acknowledgments 
We would like to thank the National Research Foundation of South Africa (NRF) for funding this project. 
We also acknowledge Dr R. Maharaj, Dr K. Moodley, Ms Zinhle Mkhize and Mr Nerolen Soobryan for 
their assistance.  
References 
1.  Barra S, do Carmo Cachulo M, Providência R, Leitão-Marques A. Hypertension in pregnancy: The 
current state of the art. Rev Port Cardiol (English Ed). 2012;31(6):425-32. 
2.  Hutcheon JA, Lisonkova S, Joseph K. Epidemiology of pre-eclampsia and the other hypertensive 
disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391-403. 
3. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. The hypertensive disorders of pregnancy 
(29.3). Best Pract & Res Clin Obstet Gynaecol. 2015;29(5):643-57. 
4. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced 
hypertension. Am J Hypertens. 2001;14(S3):178S-85S. 
5. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management 
of the hypertensive disorders of pregnancy. Preg Hypertens: An International Journal of Women's 
Cardiovascular Health. 2014;4(2):105-45. 
6. Mol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Pre-eclampsia. The 
Lancet. 2016;387(10022):999-1011. 
7. Taglauer E, Wilkins-Haug L, Bianchi D. Review: cell-free fetal DNA in the maternal circulation 
as an indication of placental health and disease. Placenta. 2014;35:S64-S8. 
8. Hill M, Barrett AN, White H, Chitty LS. Uses of cell free fetal DNA in maternal circulation. Best 
Pract Res Clin Obstet Gynaecol. 2012;26(5):639-54. 
9. Alberry M, Maddocks D, Jones M, Abdel Hadi M, Abdel-Fattah S, Avent N, et al. Free fetal DNA 
in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. 
Prenatal Diag. 2007;27(5):415-8. 
21 
 
10. Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, et al. Detection of the placental 
epigenetic signature of the maspin gene in maternal plasma. Proc Nat Acad Sci USA. 
2005;102(41):14753-8. 
11. Salvianti F, Inversetti A, Smid M, Valsecchi L, Candiani M, Pazzagli M, et al. Prospective 
evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia. Placenta. 2015;36(9):996-
1001. 
12. Saving Mothers 2011-2013. A short report of the National Committee on Confidential Enquiries 
into Maternal Deaths. Pattinson R ed. Nat Dept of Halth. Pretoria. 2015. 
13. Chan KA, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, et al. Hypermethylated 
RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of 
noninvasive prenatal diagnosis. Clin Chem. 2006;52(12):2211-8. 
14. AbdelHalim RM, Ramadan DI, Zeyada R, Nasr AS, Mandour IA. Circulating Maternal Total Cell-
Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of 
Adverse Fetal Outcome? A Cohort Study. Mol Diagn Ther. 2016;20(2):135-49. 
15. Alberry MS, Maddocks DG, Hadi MA, Metawi H, Hunt LP, Abdel-Fattah SA, et al. Quantification 
of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental 
dysfunction. Am J Obstet Gynecol. 2009;200(1):98.e1-.e6. 
16. Kim HJ, Kim SY, Lim JH, Kwak DW, Park SY, Ryu HM. Quantification and application of 
potential epigenetic markers in maternal plasma of pregnancies with hypertensive disorders. Int J 
Mol Sci. 2015;16(12):29875-88. 
17. Lazar L, Rigó J, Nagy B, Balogh K, Makó V, Cervenak L, et al. Relationship of circulating cell-
free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in 
preeclampsia. BMC Med Genet. 2009;10(1):120. 
18. Yu H, Shen Y, Ge Q, He Y, Qiao D, Ren M, et al. Quantification of maternal serum cell-free fetal 
DNA in early-onset preeclampsia. Int J Mol Sci. 2013;14(4):7571-82. 
19. Manokhina I, Singh TK, Peñaherrera MS, Robinson WP. Quantification of cell-free DNA in normal 
and complicated pregnancies: overcoming biological and technical issues. PloS one. 
2014;9(7):e101500. 
20. White HE, Dent CL, Hall VJ, Crolla JA, Chitty LS. Evaluation of a novel assay for detection of the 
fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal 
diagnosis. PloS one. 2012;7(9):e45073. 
21. Moezzi L, Keshavarz Z, Ranjbaran R, Aboualizadeh F, Behzad-Behbahani A, Abdullahi M, et al. 
Fetal RHD Genotyping Using Real-Time Polymerase Chain Reaction Analysis of Cell-Free Fetal 
DNA in Pregnancy of RhD Negative Women in South of Iran. Int J Fertili Steril. 2016;10(1):62. 
22 
 
22. Reddy A, Zhong X, Rusterholz C, Hahn S, Holzgreve W, Redman C, et al. The effect of labour 
and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free DNA and 
mRNA in normal pregnancy and pre-eclampsia. Placenta. 2008;29(11):942-9. 
23. Sekizawa A, Jimbo M, Saito H, Iwasaki M, Matsuoka R, Okai T, et al. Cell-free fetal DNA in the 
plasma of pregnant women with severe fetal growth restriction. Am Journal Obstet Gynecol. 
2003;188(2):480-4. 
24. Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH. First-trimester maternal plasma 
cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol. 2009;201(5):472. e1-. e7. 
25. Li X, Tan H, Huang X, Zhou S, Hu S, Wang X, et al. Similarities and differences between the risk 
factors for gestational hypertension and preeclampsia: A population based cohort study in south 
China. Pregn Hypertens: An International Journal of Women's Cardiovascular Health. 
2016;6(1):66-71. 
26. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, et al. Preeclampsia, gestational 
hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet 
Gynecol. 2006;194(4):921-31. 
27. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of 
placental angiogenic factors and maternal vascular function before and after preeclampsia and 
gestational hypertension. Circulation. 2010;122(5):478-87. 
28. Romero-Arauz J, Ortiz-Díaz C, Leaños-Miranda A, Martínez-Rodríguez O. [Progression of 
gestational hypertension to preeclampsia]. Ginecol Obstet Mex. 2014;82(4):229-35. 
29. Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre‐
eclampsia? BJOG: An International Journal of Obstetrics & Gynaecology. 1998;105(11):1177-84. 
30. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet 
Gynecol. 2003;102(1):181-92. 
31. Papantoniou N, Bagiokos V, Agiannitopoulos K, Kolialexi A, Destouni A, Tounta G, et al. 
RASSF1A in maternal plasma as a molecular marker of preeclampsia. Prenatal Diag. 
2013;33(7):682-7. 
32. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, 
diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from 
the ISSHP. Preg Hypertens: An International Journal of Women's Cardiovascular Health. 
2014;4(2):97-104. 
33. Lisonkova S, Joseph K. Incidence of preeclampsia: risk factors and outcomes associated with early-
versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544. e1-. e12. 
23 
 
3 CHAPTER 3: SYNTHESIS, CONCLUSION AND RECOMENDATION 
3.1 Synthesis 
Circulating cffDNA and cftDNA are novel molecular markers, and have helped change the state prenatal 
diagnosis and obstetrical research (Sifakis et al., 2015). The availability of a sensitive and reproducible 
method for early diagnosis of pregnancy complications, would help to improve clinical management of 
maternal and fetal complications (Martin et al., 2014). The circulating concentrations of cffDNA and 
cftDNA is linked to placental development, and hence any interference in this process will impact the 
circulating level of these markers (Taglauer et al., 2014). The concentration of these markers can help to 
predict complications of pregnancy, as increase in the levels occur prior to the development of clinical 
symptoms of hypertensive disorders (Sifakis et al., 2015).  
This study was designed to quantify circulating cffDNA and cftDNA in normal pregnancy and in pregnancy 
related hypertension in Black South African women, as hypertension in pregnancy remains a public health 
burden and a major cause of maternal mortality in South Africa (Saving mothers Report, 2015). Studies 
have shown that the mortality rate in black women as a result of preeclampsia is 3.1 times more than in 
Caucasians (MacKay et al., 2001). Currently no study has quantified the level cffDNA and cftDNA in a 
homogenous Black African population.   
Different studies have used various techniques for the quantification of circulating cfDNA using the 
RASSF1A gene. Some studies have used fluorescent labelled probes for the detection of the RASSF1A 
gene (Chan et al., 2006, Kim et al., 2015), while others have used SYBR green for the detection of 
fluorescence  (Moezzi et al., 2016, White et al., 2012). A modified SYBR green Real time PCR protocol 
published by White et al., for the detecting the presence of hypermethylated RASSF1A in plasma was used 
for this study (White et al., 2012). This is because White et al., (2012), found that real time qPCR data 
using SYBR green assay are easier to interpret and less complex compared to methods using the hydrolysis 
probes. These authors also showed that this technique is able to detect very low copies of the gene in plasma 
samples, is easily reproducible, less expensive and suitable for a low resource setting  (White et al., 2012). 
Extensive research has shown that circulating levels of cffDNA and cftDNA regardless of the marker 
studied (SRY gene, DSY gene; TSPY 1 gene, RASSF1A gene and DSCR3 gene); is elevated in 
preeclampsia and other pregnancy complications (AbdelHalim et al., 2016, Alberry et al., 2009, Lazar et 
al., 2009, Salvianti et al., 2015, Yu et al., 2013).  Though the SRY gene and the DSY gene can only be 
quantified in pregnancies with a male fetus, a strong correlation exist between the level of the SRY gene 
and RASSF1A gene (Manokhina et al., 2014), as well as the DSY gene and RASSF1A gene in maternal 
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circulation (White et al., 2012). This study quantified circulating cffDNA and cftDNA using the RASSF1A 
gene as it is now accepted as a universal marker for the quantification of cffDNA regardless of the sex of 
the fetus.  
The patient age and gestational age among the different groups of patients did not show any difference, and 
were matched in the present study. No difference was observed in the BMI of the PE group compared to 
the control group. The BMI of the GH was significantly higher compared to the BMI of the control group. 
In addition, there was significant difference in BMI of GH group compared to patients with PE. One of the 
risk factors of pregnancy-induced hypertension is obesity. Obesity and maternal over weight increases the 
chance of developing pregnancy induced hypertension (Rahman et al., 2015, Swank et al., 2014, Villar et 
al., 2006). Ramsay et al., (2002) have shown that obesity is associated with altered endothelial function in 
pregnancy, elevation in blood pressure, altered function of the vascular endothelium, and the upregulation 
in the production of inflammatory molecules (Ramsay et al., 2002).  
The results obtained from this study shows a 3.2-fold increase in the concentration of cffDNA and ctfDNA, 
which were significantly higher in patients with PE compared to the levels in the controls and in patients 
with GH. Our outcomes are in keeping with previous studies which have also reported increase in 
circulating of cffDNA and cftDNA in the plasma of women with preeclampsia compared to controls (Kim 
et al., 2015, Salvianti et al., 2015). Abnormal spiral artery remodelling as seen in preeclampsia leads to the 
development of an ischaemic placenta and subsequent destruction of placenta cells (Naljayan and 
Karumanchi, 2013). Destruction of the placenta cells cause the liberation of cellular contents in to the 
circulation, resulting in an increased level of circulating free fetal and total nucleic acids, microvessicles, 
and exosomes (Tannetta and Sargent, 2013). This explains the reason why these markers are elevated in 
pregnancy complications that affect the placenta such as  PE (Taglauer et al., 2014). Circulating levels of 
cffDNA and cftDNA is able to serve as a mirror image of the placenta, since the concentration of these 
markers in circulation is affected by the rate of release of cellular debris from apoptotic placenta cells 
(Taglauer et al., 2014).    These placental-derived factors/particles in circulation play significant roles in 
initiating maternal systemic inflammatory response (MSIR) and endothelial dysfunction (Tannetta and 
Sargent, 2013), and are thus central to the pathogenesis and clinical manifestations of PE. The development 
of syncytial knots and the increased infarction seen in the placenta of PE women, adds support to its role 
as a source of increased circulating cfDNA (Roberts and Post, 2008, VINNARS et al., 2011). Circulating 
levels of fetal and total cfDNA may  reflect placental status, as the concentration of these markers are 
affected by the rate of release of cellular debris from apoptotic placental cells (Taglauer et al., 2014). 
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This study has shown that GH does not affect the level of circulating cffDNA and cftDNA. The level of 
these markers in GH was significantly lower compared to the levels in PE. This result is in keeping with 
results obtained by Kim et al., (2015). These authors showed the level of cffDNA and cftDNA remained 
low in patients with GH all through in a case control study (Kim et al., 2015). Some studies show that GH, 
though a hypertensive disorder of pregnancy which shares similar risk factors and pathologic features with 
PE, is a separate condition (Li et al., 2016, Villar et al., 2006).  It has also been stated that the disequilibrium 
in the level of pro and anti-angiogenic molecules and endothelial dysfunction is a unique and peculiar 
features of PE (Noori et al., 2010). However, some authors argue that GH is likely to progress to PE and 
the rate of progress is reliant on the gestational age as at when the diagnosis of GH is made (Romero-Arauz 
et al., 2014, Saudan et al., 1998, Sibai, 2003). 
Severe forms of PE are associated with more serious maternal and fetal complications. Hence identification 
of women with preeclampsia at risk of developing severe PE will help in the management of the patient 
and averting complications associated with SPE (Fong et al., 2014). Precise diagnosis and measurement of 
risks in cases of SPE would aid in making proper and timely obstetric decisions, which cannot be achieved 
by the use of conventional and routine techniques (Fong et al., 2014, Thangaratinam et al., 2011). 
 In our study, there was 4.5 and 2.8-fold increase in the level cftDNA in SPE and MPE when compared to 
the controls, and a 5.0 and 3.6-fold increase in the concentration of cffDNA in SPE and MPE respectively. 
Fetal and total cfDNA were significantly elevated in patients with SPE compared to the level in patients 
with MPE. This finding is in keeping with findings from other studies (AbdelHalim et al., 2016, Kim et al., 
2015). Abdelhalim et al (2016) have reported an increase in the level of cffDNA and cftDNA in patients 
with SPE compared to that in MPE. Although these authors used different markers (HBB gene for 
estimation of cftDNA and the TSPY1 gene for quantification of cffDNA) for the quantification of fetal and 
total cfDNA (AbdelHalim et al., 2016). Kim et al., (2015) have also reported similar finding of an increase 
in the level of cfDNA with severity of the preeclampsia. Jakobsen et al., (2013) have stated that the levels 
of circulating cfDNA are higher in SPE than in MPE as these two conditions are different in placental 
pathological features, and hence should be managed as different entities. They also stated that increase 
cffDNA which is seen in cases of SPE results from an increase in the release of syncytiotrophoblast from 
ischemic lesions (Jakobsen et al., 2013).   
This finding of an increase in cffDNA and cftDNA in SPE compared to MPE might help clinicians 
differentiate SPE from MPE, and help in accurate risk assessment in cases of SPE thus providing 
information needed for timing of delivery. This aspect requires further investigation.   
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Studies have shown that EOPE and LOPE are distinct entities with different pathologies (Von Dadelszen 
et al., 2003, Walker, 2000). These entities differ in pathological features and in maternal and fetal outcomes 
(Raymond and Peterson, 2011). Masuyama et al., (2010) have stated that angiogenic factor levels varies 
between EOPE and LOPE. EOPE is associated more with altered cardiovascular function resulting from 
placental disorder while LOPE is related more to maternal factors (Valensise et al., 2008). The finding from 
this current study shows a significant increase in the level of circulating cffDNA and cftDNA in EOPE and 
LOPE groups compared to the level in the control group, but the level did not vary between EOPE and 
LOPE.  This finding is in keeping with the study carried out by Papantoniou et al., who noted the level of 
cffDNA in EOPE was not different from the level in LOPE, though the number EOPE to LOPE in their 
study was only 2 out of a total 24 preeclamptic women (Papantoniou et al., 2013). Though the results 
obtained in this study did not show any difference in the level of circulating cffDNA and cftDNA between 
EOPE compared to LOPE, Papantoniou et al., (2013) have shown that the circulation levels of these markers 
can be used to identify women who are likely to develop preeclampsia at an early stage, as the circulating 
concentration of fetal and total DNA in this women are elevated in the early stages of pregnancy. These 
authors have also stated that the increase in the level of circulating cfDNA in the early stages of pregnancy 
correlates to the altered placentation which is an initiating factor of PE (Papantoniou et al., 2013). This 
finding supports the hypothesis that cfDNA elevation in PE is due to impaired trophoblastic invasion of 
maternal spiral arteries leading to placental ischemia and damage, with the consequent release of apoptotic 
syncytiotrophoblast fragments that contain fetal DNA. 
 
3.2 Conclusions  
In conclusion, results from this study indicate that circulating cffDNA and cftDNA is elevated in 
preeclampsia. Consideration needs to be given to its potential use as a biomarker in the diagnosis and 
monitoring of complications of pregnancy. Our results also indicate that the level of severity of PE may be 
a factor that influences the level of these markers in maternal plasma in PE. This is promising as it can be 
used in making appropriate and timely decisions in patient management with SPE, and in the timing of 
delivery.  
3.3 Recommendations 
Several studies have shown that the level of circulating cffDNA and cftDNA are increased in preeclampsia. 
These results from previous studies show variations, as the level of increase differs with the study. It is 
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therefore necessary that the use of cfDNA alone or in combination with other tests be fully standardised for 
the diagnosis and monitoring of preeclampsia and other complications of pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
4 REFERENCES 
 
Abalos, E., Cuesta, C., Grosso, A. L., Chou, D. & Say, L. 2013. Global and regional estimates of 
preeclampsia and eclampsia: a systematic review. European Journal of Obstetrics & Gynecology 
and Reproductive Biology, 170, 1-7. 
Abdelhalim, R. M., Ramadan, D. I., Zeyada, R., Nasr, A. S. & Mandour, I. A. 2016. Circulating Maternal 
Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: 
Predictors of Adverse Fetal Outcome? A Cohort Study. Molecular diagnosis & therapy, 20, 135-
149. 
Alberry, M., Maddocks, M., Jones, M., Abdel Hadi, M., Abdel-Fattah, S., Avent, N. & Soothill, P. 2007. 
Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the 
trophoblast. Prenatal diagnosis, 27, 415-418. 
Alberry, M. S., Maddocks, D. G., Hadi, M. A., Metawi, H., Hunt, L. P., Abdel-Fattah, S. A., Avent, N. D. 
& Soothill, P. W. 2009. Quantification of cell free fetal DNA in maternal plasma in normal 
pregnancies and in pregnancies with placental dysfunction. American Journal of Obstetrics and 
Gynecology, 200, 98.e1-98.e6. 
Barra, G. B., Santa Rita, T. H., De Almeida Vasques, J., Chianca, C. F., Nery, L. F. A. & Costa, S. S. S. 
2015. EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo 
degradation in blood samples. Clinical biochemistry.48, 976-981 
Barra, S., Do Carmo Cachulo, M., Providência, R. & Leitão-Marques, A. 2012. Hypertension in pregnancy: 
The current state of the art. Revista Portuguesa de Cardiologia (English Edition), 31, 425-432. 
BianchI, D. 2004. Circulating fetal DNA: its origin and diagnostic potential—a review. Placenta, 25, S93-
S101. 
Borzychowski, A. M., Sargent, I. L. & Redman, C. W. G. 2006. Inflammation and pre-eclampsia. Seminars 
in Fetal and Neonatal Medicine, 11, 309-316. 
Chan, K. A., Ding, C., Gerovassili, A., Yeung, S. W., Chiu, R. W., Leung, T. N., Lau, T. K., Chim, S. S., 
Chung, G. T. & Nicolaides, K. H. 2006. Hypermethylated RASSF1A in maternal plasma: a 
29 
 
universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clinical 
chemistry, 52, 2211-2218. 
Chim, S. S., Tong, Y. K., Chiu, R. W., Lau, T. K., Leung, T. N., Chan, L. Y., Oudejans, C. B., Ding, C. & 
Lo, Y. D. 2005. Detection of the placental epigenetic signature of the maspin gene in maternal 
plasma. Proceedings of the National Academy of Sciences of the United States of America, 102, 
14753-14758. 
Craici, I. M., Wagner, S. J., Bailey, K. R., Fitz-Gibbon, P. D., Wood-Wentz, C. M., Turner, S. T., Hayman, 
S. R., White, W. M., Brost, B. C. & Rose, C. H. 2013. Podocyturia Predates Proteinuria and Clinical 
Features of Preeclampsia Longitudinal Prospective Study. Hypertension, 61, 1289-1296. 
Cruz, M. O., Gao, W. & Hibbard, J. U. 2012. What is the optimal time for delivery in women with 
gestational hypertension? American Journal of Obstetrics and Gynecology, 207, 214.e1-214.e6. 
Cuckle, H., Benn, P. & Pergament, E. 2015. Cell-free DNA screening for fetal aneuploidy as a clinical 
service. Clinical Biochemistry. 48, 932-941. 
Daniels, G., Finning, K., Martin, P. & Massey, E. 2009. Noninvasive prenatal diagnosis of fetal blood group 
phenotypes: current practice and future prospects. Prenatal diagnosis, 29, 101-107. 
Devaney, s. a., Palomaki, G. E., Scott, J. A. & Bianchi, D. W. 2011. Noninvasive fetal sex determination 
using cell-free fetal DNA: a systematic review and meta-analysis. Jama, 306, 627-636. 
Eastabrook, G., Brown, M. & Sargent, I. 2011. The origins and end-organ consequence of pre-eclampsia. 
Best Practice & Research Clinical Obstetrics & Gynaecology, 25, 435-447. 
Fong, F. M., Sahemey, M. K., Hamedi, G., Eyitayo, R., Yates, D., Kuan, V., Thangaratinam, S. & Walton, 
R. T. 2014. Maternal genotype and severe preeclampsia: a HuGE review. American Journal of 
Epidemiology, 180, 335-345. 
Ghulmiyyah, L. & Sibai, B. 2012. Maternal Mortality From Preeclampsia/Eclampsia. Seminars in 
Perinatology, 36, 56-59. 
Goulopoulou, S. & Davidge, S. T. 2015. Molecular mechanisms of maternal vascular dysfunction in 
preeclampsia. Trends in molecular medicine, 21, 88-97. 
30 
 
Granger, J. P., Alexander, B. T., Bennett, W. A. & Khalil, R. A. 2001. Pathophysiology of pregnancy-
induced hypertension. American Journal of Hypertension, 14, 178S-185S. 
Hahn, S., Giaglis, S., Buser, A., Hoesli, I., Lapaire, O. & Hasler, P. 2014. Cell-free nucleic acids in 
(maternal) blood: any relevance to (reproductive) immunologists? Journal of reproductive 
immunology, 104, 26-31. 
Hahn, S., Rusterholz, C., Hösli, I. & Lapaire, O. 2011. Cell-free nucleic acids as potential markers for 
preeclampsia. Placenta, 32, S17-S20. 
Hill, M., Barrett, A. N., White, H. & Chitty, L. S. 2012. Uses of cell free fetal DNA in maternal circulation. 
Best Practice & Research Clinical Obstetrics & Gynaecology, 26, 639-654. 
Huppertz, B. 2004. Apoptosis in the trophoblast—role of apoptosis in placental morphogenesis. Journal of 
the Society for Gynecologic Investigation, 11, 353-362. 
Hutcheon, J. A., Lisonkova, S. & Joseph, K. 2011. Epidemiology of pre-eclampsia and the other 
hypertensive disorders of pregnancy. Best practice & research Clinical obstetrics & gynaecology, 
25, 391-403. 
Jakobsen, T. R., Clausen, F. B., Rode, l., Dziegiel, M. H. & Tabor, A. 2013. Identifying mild and severe 
preeclampsia in asymptomatic pregnant women by levels of cell‐free fetal DNA. Transfusion, 53, 
1956-1964. 
Kim, H. J., Kim, S. Y., Lim, J. H., Kwak, D. W., Park, S. Y. & Ryu, H. M. 2015. Quantification and 
application of potential epigenetic markers in maternal plasma of pregnancies with hypertensive 
disorders. International journal of molecular sciences, 16, 29875-29888. 
Lazar, L., Rigó, J., Nagy, B., Balogh, K., Makó, V., Cervenak, L., Mézes, M., Prohászka, Z. & Molvarec, 
A. 2009. Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical 
characteristics and laboratory parameters in preeclampsia. BMC medical genetics, 10, 120. 
Li, X., Tan, H., Huang, X., Zhou, S., Hu, S., Wang, X., Xu, X., Liu, Q. & Wen, S. W. 2016. Similarities 
and differences between the risk factors for gestational hypertension and preeclampsia: A 
population based cohort study in south China. Pregnancy Hypertension: An International Journal 
of Women's Cardiovascular Health, 6, 66-71. 
31 
 
Lin, S., Leonard, D., Co, M. A. M., Mukhopadhyay, D., Giri, B., Perger, L., Beeram, M. R., Kuehl, T. J. & 
Uddin, M. N. 2015. Pre-eclampsia has an adverse impact on maternal and fetal health. 
Translational Research, 165, 449-463. 
Lisonkova, S. & Joseph, K. 2013. Incidence of preeclampsia: risk factors and outcomes associated with 
early-versus late-onset disease. American journal of obstetrics and gynecology, 209, 544. e1-544. 
e12. 
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W. G. & WAINSCOAT, 
J. S. 1997. Presence of fetal DNA in maternal plasma and serum. The Lancet, 350, 485-487. 
Lui, Y. Y., Chik, K.-W., Chiu, R. W., Ho, C.-Y., Lam, C. W. & Lo, Y. D. 2002. Predominant hematopoietic 
origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. 
Clinical chemistry, 48, 421-427. 
Mackay, A. P., Berg, C. J. & Atrash, H. K. 2001. Pregnancy‐related mortality from preeclampsia and 
eclampsia. Obstetrics & Gynecology, 97, 533-538. 
Magee, L. A., Pels, A., Helewa, M., Rey, E. & Von Dadelszen, P. 2014. Diagnosis, evaluation, and 
management of the hypertensive disorders of pregnancy. Pregnancy Hypertension: An 
International Journal of Women's Cardiovascular Health, 4, 105-145. 
Magee, L. A., Pels, A., Helewa, M., Rey, E. & Von Dadelszen, P. 2015. The hypertensive disorders of 
pregnancy (29.3). Best Practice & Research Clinical Obstetrics & Gynaecology, 29, 643-657. 
Mandel, P. M., P 1948. Les acides nucleiques du plasma sanguin chez l’Homme. C R Acad Sci Paris, 142, 
241-243. 
Manokhina, I., Singh, T. K., Peñaherrera, M. S. & Robinson, W. P. 2014. Quantification of cell-free DNA 
in normal and complicated pregnancies: overcoming biological and technical issues. PloS one, 9, 
e101500. 
Martin, A., Krishna, I., Martina, B. & Samuel, A. 2014. Can the quantity of cell‐free fetal DNA predict 
preeclampsia: a systematic review. Prenatal diagnosis, 34, 685-691. 
Masuyama, H., Segawa, T., Sumida, Y., Masumoto, A., Inoue, S., Akahori, Y. & Hiramatsu, Y. 2010. 
Different profiles of circulating angiogenic factors and adipocytokines between early‐and late‐
onset pre‐eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology, 117, 314-320. 
32 
 
Moezzi, L., Keshavarz, Z., Ranjbaran, R., Aboualizadeh, F., Behzad-Behbahani, A., Abdullahi, M., 
Ramezani, A., Samsami, A. & Sharifzadeh, S. 2016. Fetal RHD Genotyping Using Real-Time 
Polymerase Chain Reaction Analysis of Cell-Free Fetal DNA in Pregnancy of RhD Negative 
Women in South of Iran. International journal of fertility & sterility, 10, 62. 
Mol, B. W., Roberts, C. T., Thangaratinam, S., Magee, L. A., De Groot, C. J. & Hofmeyr, G. J. 2016. Pre-
eclampsia. The Lancet, 387, 999-1011. 
Moodley, J. 2011. Maternal deaths associated with hypertension in South Africa: lessons to learn from the 
Saving Mothers report, 2005–2007. Cardiovascular journal of Africa, 22, 31. 
Naljayan, M. V. & Karumanchi, S. A. 2013. New developments in the pathogenesis of preeclampsia. 
Advances in chronic kidney disease, 20, 265-270. 
Noori, M., Donald, A. E., Angelakopoulou, A., Hingorani, A. D. & Williams, D. J. 2010. Prospective study 
of placental angiogenic factors and maternal vascular function before and after preeclampsia and 
gestational hypertension. Circulation, 122, 478-487. 
Osungbade, K. O. & Ige, O. K. 2011. Public health perspectives of preeclampsia in developing countries: 
implication for health system strengthening. Journal of pregnancy, 2011. 
Papantoniou, N., Bagiokos, V., Agiannitopoulos, K., Kolialexi, A., Destouni, A., Tounta, G., Kanavakis, 
E., Antsaklis, A. & Mavrou, A. 2013. RASSF1A in maternal plasma as a molecular marker of 
preeclampsia. Prenatal diagnosis, 33, 682-687. 
Powe, C. E., Levine, R. J. & Karumanchi, S. A. 2011. Preeclampsia, a disease of the maternal endothelium 
the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation, 
123, 2856-2869. 
Rahman, M., Abe, S., Kanda, M., Narita, S., Rahman, M., Bilano, V., Ota, E., Gilmour, S. & Shibuya, K. 
2015. Maternal body mass index and risk of birth and maternal health outcomes in low‐and middle‐
income countries: a systematic review and meta‐analysis. Obesity Reviews, 16, 758-770. 
Ramsay, J. E., Ferrell, W. R., Crawford, L., Wallace, A. M., Greer, I. A. & Sattar, N. 2002. Maternal obesity 
is associated with dysregulation of metabolic, vascular, and inflammatory pathways. The Journal 
of Clinical Endocrinology & Metabolism, 87, 4231-4237. 
33 
 
Raymond, D. & Peterson, E. 2011. A critical review of early-onset and late-onset preeclampsia. Obstetrical 
& gynecological survey, 66, 497-506. 
Reddy, A., Zhong, X., Rusterholz, C., Hahn, S., Holzgreve, W., Redman, C. & Sargent, I. 2008. The effect 
of labour and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free 
DNA and mRNA in normal pregnancy and pre-eclampsia. Placenta, 29, 942-949. 
Redman, C. W. G. 2011. Preeclampsia: A multi-stress disorder. La Revue de Médecine Interne, 32, 
Supplement 1, S41-S44. 
Redman, C. W. G. & Sargent, I. L. 2001. The pathogenesis of pre-eclampsia. Gynécologie Obstétrique & 
Fertilité, 29, 518-522. 
Romero-Arauz, J., Ortiz-Díaz, C., Leaños-Miranda, A. & Martínez-Rodríguez, O. 2014. [Progression of 
gestational hypertension to preeclampsia]. Ginecologia y obstetricia de Mexico, 82, 229-235. 
Salvianti, F., Inversetti, A., Smid, M., Valsecchi, L., Candiani, M., Pazzagli, M., Cremonesi, L., Ferrari, 
M., Pinzani, P. & Galbiati, S. 2015. Prospective evaluation of RASSF1A cell-free DNA as a 
biomarker of pre-eclampsia. Placenta, 36, 996-1001. 
Saudan, P., Brown, M. A., Buddle, M. L. & Jones, M. 1998. Does gestational hypertension become pre‐
eclampsia? BJOG: An International Journal of Obstetrics & Gynaecology, 105, 1177-1184. 
Saving Mothers 2011-2013. A short report of the National Committee on Confidential Enquiries into 
Maternal Deaths. Pattinson R ed. Nat Dept of Halth. Pretoria. 2015. 
Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A.-B., Daniels, J., Gülmezoglu, A. M., Temmerman, 
M. & Alkema, L. 2014. Global causes of maternal death: a WHO systematic analysis. The Lancet 
Global Health, 2, e323-e333. 
Sekizawa, A., Jimbo, M., Saito, H., Iwasaki, M., Matsuoka, R., Okai, T. & Farina, A. 2003. Cell-free fetal 
DNA in the plasma of pregnant women with severe fetal growth restriction. American Journal of 
Obstetrics and Gynecology, 188, 480-484. 
Sekizawa, A., Kondo, T., Iwasaki, M., Watanabe, A., Jimbo, M., Saito, H. & Okai, T. 2001. Accuracy of 
fetal gender determination by analysis of DNA in maternal plasma. Clinical chemistry, 47, 1856-
1858. 
34 
 
Shah, D. M. 2007. Preeclampsia: new insights. Current opinion in nephrology and hypertension, 16, 213-
220. 
Sibai, B. M. 2003. Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics & 
Gynecology, 102, 181-192. 
Sibai, B. M. 2011. Management of Late Preterm and Early-Term Pregnancies Complicated by Mild 
Gestational Hypertension/Pre-Eclampsia. Seminars in Perinatology, 35, 292-296. 
Sifakis, S., Koukou, Z. & Spandidos, D. A. 2015. Cell-free fetal DNA and pregnancy-related complications 
(Review). Molecular medicine reports, 11, 2367-2372. 
Sifakis, S., Zaravinos, A., Maiz, N., Spandidos, D. A. & Nicolaides, K. H. 2009. First-trimester maternal 
plasma cell-free fetal DNA and preeclampsia. American journal of obstetrics and gynecology, 201, 
472. e1-472. e7. 
Souza, J. P., Gülmezoglu, A. M., Vogel, J., Carroli, G., Lumbiganon, P., Qureshi, Z., Costa, M. J., Fawole, 
B., Mugerwa, Y. & Nafiou, I. 2013. Moving beyond essential interventions for reduction of 
maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-
sectional study. The Lancet, 381, 1747-1755. 
Steegers, E. A. P., Von dadelszen, P., Duvekot, J. J. & Pijnenborg, R. 2010. Pre-eclampsia. The Lancet, 
376, 631-644. 
Swank, M., Caughey, A., Farinelli, C., Main, E., Melsop, K., Gilbert, W. & Chung, J. 2014. The impact of 
change in pregnancy body mass index on the development of gestational hypertensive disorders. 
Journal of Perinatology, 34. 
Taglauer, E., Wilkins-Haug, L. & Bianchi, D. 2014. Review: cell-free fetal DNA in the maternal circulation 
as an indication of placental health and disease. Placenta, 35, S64-S68. 
Tannetta, D. & Sargent, I. 2013. Placental disease and the maternal syndrome of preeclampsia: missing 
links? Current hypertension reports, 15, 590-599. 
Thangaratinam, S., Koopmans, C. M., Iyengar, S., Zamora, J., Ismail, K. M., Mol, B. W. & Khan, K. S. 
2011. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women 
with preeclampsia: a systematic review. Acta obstetricia et gynecologica Scandinavica, 90, 574-
585. 
35 
 
Tranquilli, A. L., Dekker, G., Magee, L., Roberts, J., Sibai, B. M., Steyn, W., Zeeman, G. G. & Brown, M. 
A. 2014. The classification, diagnosis and management of the hypertensive disorders of pregnancy: 
A revised statement from the ISSHP. Pregnancy Hypertension: An International Journal of 
Women's Cardiovascular Health, 4, 97-104. 
Valensise, H., Vasapollo, B., Gagliardi, G. & Novelli, G. P. 2008. Early and late preeclampsia two different 
maternal hemodynamic states in the latent phase of the disease. Hypertension, 52, 873-880. 
Villar, J., Carroli, G., Wojdyla, D., Abalos, E., Giordano, D., Ba'Aqeel, H., Farnot, U., Bergsjø, P., 
Bakketeig, L., Lumbiganon, P., Campodónico, L., Al-Mazrou, Y., Lindheimer, M. & Kramer, M. 
2006. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or 
independent conditions? American Journal of Obstetrics and Gynecology, 194, 921-931. 
Von Dadelszen, P., Magee, L. A. & Roberts, J. M. 2003. Subclassification of preeclampsia. Hypertension 
in pregnancy, 22, 143-148. 
Walker, J. J. 2000. Pre-eclampsia. The Lancet, 356, 1260-1265. 
Watanabe, K., Naruse, K., Tanaka, K., Metoki, H. & Suzuki, Y. 2013. Outline of definition and 
classification of “pregnancy induced hypertension (PIH)”. Hypertension Research in Pregnancy, 
1, 3-4. 
Watson, J. D. & Crick, F. H. The structure of DNA.  Cold Spring Harbor Symposia on Quantitative Biology, 
1953. Cold Spring Harbor Laboratory Press, 123-131. 
White, H. E., Dent, C. L., Hall, V. J., Crolla, J. A. & Chitty, L. S. 2012. Evaluation of a novel assay for 
detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive 
prenatal diagnosis. PloS one, 7, e45073. 
Yu, H., Shen, Y., Ge, Q., He, Y., Qiao, D., Ren, M. & Zhang, J. 2013. Quantification of maternal serum 
cell-free fetal DNA in early-onset preeclampsia. International journal of molecular sciences, 14, 
7571-7582. 
Zejskova, L., Jancuskova, T., Kotlabova, K., Doucha, J. & Hromadnikova, I. 2010. Feasibility of fetal-
derived hypermethylated RASSF1A sequence quantification in maternal plasma—Next step 
toward reliable non-invasive prenatal diagnostics. Experimental and molecular pathology, 89, 241-
247. 
36 
 
 
APENDIX A 
 
 
Figure 1. Standard curve using known concentration of genomic DNA to determine the concentration of 
circulating cffDNA and cftDNA in plasma. 
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Ethical Approval from the University of Kwazulu-Natal Biomedical Research Ethics Committee (BREC) 
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APENDIX E 
 
DATA SHEET: characterising cell free DNA in normal pregnancy and in hypertensive disorders of 
pregnancy in black South African women. 
Study site: ………………………………………………Study number: ……………………………….  
Study groups:  Normotensive, Gestational hypertension, Mild/moderate Preeclampsia, Severe 
Preeclampsia. 
GENERAL HOSPITAL INFORMATION: 
Hospital number  Admission number 
  
PATIENT DEMOGRAPHICS: 
Date of Birth Rural dweller Urban dweller Life style 
    
Clinical Data 
Gravidity  
Parity  
Gestational age  
Maternal Height  
Maternal weight  
Systolic blood pressure  
Diastolic blood pressure  
Proteinuria  
HIV Status  
If HIV positive, CD4 count  
BABY OUTCOME: 
Baby’s Birth Weight: 
Baby’s gender: 
Favourable /unfavourable 
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APENDIX F 
 
INFORMED CONSENT FORM 
Consent to Participate in Research  
Dear Ms, Miss, Mrs: 
I am sister Mkhize, carrying out a study with Mr Eche who is studying for a masters degree at University 
of Kwazulu-Natal .We will require half a tea spoon (5ml) of blood from you. We will take the blood the 
same time your doctors are take their blood samples for antenatal care. The taking of blood may cause you 
slight discomfort. 
Our study may lead to finding out whether we can diagnose people with high blood pressure in early 
pregnancy. This may not be of help to you at the moment, but in future it may be of help to other pregnant 
women. Your taking part in this study is on your own free will (voluntary) and you can refuse. If you do 
not want to be in the study, you will not be treated differently from other patients. Our study also does not 
interfere with the normal treatment you get.  
The results of this study will be published but no names will be used. The reason for publishing is so that 
other doctors and nurses can learn about our findings and because Mr Eche will get a higher qualification. 
Note that we may ask you a few questions about your previous pregnancy and this current pregnancy, the 
same questions asked at the time of your first visit to the clinic. All the information will be kept in a locked 
cupboard and burnt/ destroyed once the study is over. 
Please do not hesitate to let me know if you would like more information.  
Thank You 
____________________                                                       ____________________  
Signature of Participant                                                                        Date  
 
____________________                                                        _____________________  
Signature of Witness Date  
(Ms P Mkhize)  
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